Harbour BioMed's Partner Spruce Biosciences Separates CRHX-101 Program Into Adrenyx Biosciences, Advancing Development of Harbour BioMed-Originated Antibody Through a Standalone Company
- Spruce Biosciences separated its CRHX-101 program into Adrenyx Biosciences, a wholly owned subsidiary focused on endocrinology.
- Adrenyx is expected to be listed on Nasdaq during the first half of 2027.
- Harbour BioMed expects to hold interests in both Spruce and Adrenyx after a planned stock distribution to Spruce shareholders.
- Adrenyx plans to prepare CRHX-101 for regulatory review and begin clinical development after filing an application with the U.S. Food and Drug Administration.
25 Articles
25 Articles
Harbour BioMed's Partner Spruce Biosciences Separates CRHX-101 Program into Adrenyx Biosciences, Advancing Development of Harbour BioMed-Originated Antibody through a Standalone Company
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Nov. 17, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced that…
Harbour BioMed's Partner Spruce Biosciences Separates CRHX-101 Program into Adrenyx Biosciences, Advancing Development of Harbour BioMed-Originated Antibody through a Standalone Company - PressReach
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Nov. 17, 2026 /PRNewswire/ — Harbour BioMed (the “Company”; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced that its partner Spruce Biosciences (Nasdaq: SPRB) (“Spruce”) has separated its CRHX-101 (formerly SPR-202 and HBM9013) program … Continue reading "Harbou…
Coverage Details
Bias Distribution
- 70% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium















